Guidelines for Cervical Cancer Screening and Management – Pearls and Perils

 

Eric C. Huang, MD, PhD
Associate Professor, Director of Cytopathology, Fellowship Program,
HPV Molecular Diagnostic Laboratory
University of Washington Harborview Medical Center
Seattle, Washington

 

A standard approach to managing patients with abnormal cervical cytology and cervical cancer precursors was initially developed by ASCCP in 2001. Since then, our understanding of cervical disease has advanced, and screening has changed. Cytologists would benefit from guidance on how to incorporate the newly developed risk-based management guidelines into their routine practice. Attendees will learn the risk estimates based on patient characteristics and current and prior test results. In addition, current screening strategy has shifted to primary HPV as the preferred method. The impact of primary HPV screening will be presented. After this webinar, the attendees will understand the current screening and management guidelines in cervical cancer screening.

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • Describe the current cervical cancer screening guidelines
  • Apply the latest ASCCP risk-based management guidelines for cervical abnormalities
  • Understand the pearls and pitfalls of primary HPV screening
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant
Course opens: 
11/26/2024
Course expires: 
11/25/2027
Cost:
$105.00

Presenter(s):
Eric C. Huang, MD, PhD

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:
Christopher J. VandenBussche MD PhD: Ad hoc advisory board panel and Consultant – Roche

The following individuals have reported no relevant financial relationships:
Susan Alperstein, MS, CT(ASCP), Kristen Atkins, MD, Catherine Bammert, PhD, CT, MB(ASCP), Christine Booth, MD, Deborah Chute, MD, Amy Clayton, MD, Jacqueline Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Beverly Haigler-Daly, BS, CT(ASCP), Michael Henry, MD, Oscar Lin, MD, PhD, Sean McNair, MPH, CT(ASCP), Michelle Reid, MD, Sinchita Roy-Chowdhuri, MD, PhD, Momin Siddiqui, MD, FIAC, Liron Pantanowitz, MD, PhD, MHA, Michelle Reid, MD, Sinchita Roy-Chowdhuri, MD, PhD, Momin Siddiqui, MD, FIAC, Michael Thrall, MD, Vivian Weiss, MD, PhD, Donna Armylagos, BA CT(ASCP), Cheryl K. Arnott, SCT(ASCP), Bonnie Choy, MD, Saroja Devi Geetha, MBBS, Elizabeth Jacobi, MD, Jennifer B. Kernodle-Zimmer, BS, SCT(ASCP), Zaibo Li, MD, PhD, Steven Long, MD, Judy Pang, MD, Ami Patel, MD, Maria Luisa Policarpio-Nicolas, MD, Jose Victor Scarpa Carniello, MD, Sheila Segura, MD, Paul Staats, MD, Peter Wanes, MD

The ASC staff associated with the development of content for this activity reported no relevant financial relationships.

Presenter:
The presenter has no conflicts of interest or financial relationships to disclose.

ACCREDITATION AND DESIGNATION STATEMENTS

Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Continuing Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 2.0 Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 1.00 California Credits
  • 2.00 CMLE
  • 2.00 Florida Credits
  • 2.00 Participant

Price

Cost:
$105.00
Please login or register to take this course.